Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | DPP4 | P27487 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.62 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.62 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.62 |
| ▸ | GAPDH | P04406 | 1/20 | 0.62 |
| ▸ | STAT6 | P42226 | 1/20 | 0.62 |
| ▸ | PI4KA | P42356 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.62 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.62 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.62 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.62 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1434130 | 0.92 | ADORA1 (0.67) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL932846 | 0.90 | ADORA1 (0.65) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL13269023 | 0.89 | ADORA1 (0.58) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL8328542 | 0.89 | ADORA1 (0.74) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL7860970 | 0.87 | ADORA1 (0.57) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL13268940 | 0.87 | ADORA2A (0.57) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL13269089 | 0.86 | ADORA2A (0.64) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL2270709 | 0.86 | ADORA1 (0.73) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL6828798 | 0.86 | ADORA1 (0.70) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL13269099 | 0.85 | ADORA2A (0.57) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201240-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | CAN-FITE BIOPHARMA LTD. (IL) | 2023-06-29 | — | — | US | claimed |
| EP-3906034-A1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT | Can-Fite Biopharma Ltd. (IL) | 2021-11-10 | — | — | EP | claimed |
| US-20210069227-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR MANAGING CYTOKINE RELEASE SYNDROME | CAN-FITE BIOPHARMA LTD (IL) | 2021-03-11 | — | — | US | claimed |
| EP-3681538-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR MANAGING CYTOKINE RELEASE SYNDROME | Can-Fite Biopharma Ltd. (IL) | 2020-07-22 | — | — | EP | claimed |
| WO-2020141535-A1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE FOR ACHIEVING A FAT LOSS EFFECT | CAN-FITE BIOPHARMA LTD. (IL) | 2020-07-09 | — | — | WO | claimed |
| EP-3530273-A2 | A3 ADENOSINE RECEPTOR LIGANDS FOR USE IN TREATMENT OF A SEXUAL DYSFUNCTION | Can-Fite Biopharma Ltd. (IL) | 2019-08-28 | — | — | EP | claimed |
| WO-2019053723-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR MANAGING CYTOKINE RELEASE SYNDROME | CAN-FITE BIOPHARMA LTD (IL) | 2019-03-21 | — | — | WO | claimed |
| EP-3380104-A1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION | Can-Fite Biopharma Ltd. (IL) | 2018-10-03 | — | — | EP | claimed |
| WO-2017090036-A1 | AN A3 ADENOSINE RECEPTOR LIGAND FOR USE IN TREATING ECTOPIC FAT ACCUMULATION | CAN-FITE BIOPHARMA LTD. (IL) | 2017-06-01 | — | — | WO | claimed |
| US-9549943-B2 | A3 adenosine receptor ligands for use in treatment of a sexual dysfunction | CAN-FITE BIOPHARMA LTD. (IL) | 2017-01-24 | — | — | US | claimed |
| EP-1383515-B1 | ACTIVATION OF NATURAL KILLER CELLS BY ADENOSINE A3 RECEPTOR AGONISTS | CAN FITE BIOPHARMA LTD (IL) | 2004-12-15 | — | — | EP | claimed |
| US-20040204481-A1 | Activation of natural killer cells by adenosine A3 receptor agonists | CAN-FITE BIOPHARMA LTD. (IL) | 2004-10-14 | — | — | US | claimed |
| WO-2004088312-A2 | FLUORESCENTLY TAGGED LIGANDS | UNIVERSITY OF NOTTINGHAM (GB) | 2004-10-14 | — | — | WO | claimed |
| JP-2004520404-A | — | — | 2004-07-08 | — | — | JP | claimed |
| EP-1383515-A1 | ACTIVATION OF NATURAL KILLER CELLS BY ADENOSINE A3 RECEPTOR AGONISTS | Can-Fite Biopharma Ltd. (IL) | 2004-01-28 | — | — | EP | claimed |
| EP-1363644-A2 | MODULATION OF GSK-3BETA ACTIVITY AND ITS DIFFERENT USES | Can-Fite Biopharma Ltd. (IL) | 2003-11-26 | — | — | EP | claimed |
| US-20020165197-A1 | Administering adenosine receptor ligand | CAN-FITE BIOPHARMA LTD. (IL) | 2002-11-07 | — | — | US | claimed |
| WO-2002083152-A1 | ACTIVATION OF NATURAL KILLER CELLS BY ADENOSINE A3 RECEPTOR AGONISTS | CAN-FITE BIOPHARMA LTD. (IL) | 2002-10-24 | — | — | WO | claimed |
| WO-2002066020-A2 | MODULATION OF GSK-3BETA ACTIVITY AND ITS DIFFERENT USES | CAN-FITE BIOPHARMA LTD. (IL) | 2002-08-29 | — | — | WO | claimed |
| US-20020115635-A1 | Modulation of GSK-3beta activity and its different uses | CAN-FITE TECHNOLOGIES LTD. (IL) | 2002-08-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201240-A1 | TREATMENT OF ADVANCED METASTATIC CANCER | ADORA3, ADORA2A, ADORA1 | ADORA1 3/4885SMN1; SMN2 4028/4885ADORA3 1/4885 |
| US-20040204481-A1 | Activation of natural killer cells by adenosine A3 receptor agonists | ADORA3, ADORA2A, ADORA1 | ADORA1 3/4885SMN1; SMN2 3939/4885ADORA3 1/4885 |
| US-20210069227-A1 | A3 ADENOSINE RECEPTOR LIGAND FOR MANAGING CYTOKINE RELEASE SYNDROME | ADORA3, ADORA2A, IL1RN | ADORA1 5/4885SMN1; SMN2 4203/4885ADORA3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.